Azima-500 LB batch fails test, recall reported
Batch GT30389J did not meet the stated Lactic Acid Bacillus assay requirement. Telangana’s recall instructions are reported, but the underlying advisory is not publicly available in the material reviewed.
Batch GT30389J was classified as Not of Standard Quality after failing its stated Lactic Acid Bacillus assay requirement.
A batch of Azima-500 LB tablets has been classified as Not of Standard Quality after testing found that its Lactic Acid Bacillus assay did not conform to the stated requirement. The affected batch is GT30389J, manufactured by J.M. Laboratories in December 2025 and marked to expire in November 2027. The test was conducted by the Central Drugs Laboratory, Kolkata, and appears in the August 2026 quality-alert data.
A published report says the Telangana Drugs Control Administration and TG SAFE ordered an urgent recall, advising the public not to consume batch GT30389J and directing chemists and stockists to withdraw it. Patients were reportedly advised to consult a doctor or pharmacist about alternatives. The underlying TGDCA/TG SAFE notice, however, was not available in the official pages reviewed. The regulator’s public database does confirm that it maintains records of drugs declared “Not of Standard Quality / Misbranded”.
The sources reviewed contain no confirmed report of injury, adverse reaction or death linked to this batch. They also do not state how much reached Telangana, how many pharmacies were affected, or whether the recall extends beyond the state. The manufacturer’s response was not located. The batch failed a quality specification; that is the record, and it is not a finding that every tablet is toxic.